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When the endothelial cells (ECs) were stimulated with y-interferon (gIFW) in the presence of methylprednisolone (MP) 
or prostaglandin & (PGE,), MP enhanced gIFN-induced Ia antigen expression, whereas PGE, inhibited it. On the other 
hand, while PGE, had no effect on leucocyte binding to ECs, MP entirely inhibited it. By using selective inhibitors of 
the cycle-oxygenase pathway (indomethacin, IM) and the S-lipoxygenase pathway (L651.392), we found that addition 
of IM to gIFN-stimulated ECs enhanced Ia expression but had no effect on leucocyte adherence to ECs. Instead, addition 
of L651.392 to gIFN-stimulated ECs partially reduced leucocyte adherence to ECs but had no effect on Ia expression. 
Pretreatment of the ECs or leucocytes or both with monoclonal anti-class II antibody, had no effect on gIFN-induced 
leucocyte binding to ECs. These findings suggest that gIFN-induced endothelial cell antigenicity and leucocyte adherence 
are regulated independently of each other by different molecular pathways. Moreover, arachidonic acid metabolites ap- 
pear to be the regulatory molecules in gIFN effects on the ECs. 
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1. INTRODUCTION 
Graft endothelial cells (ECs) play an important 
role in the initiation and maintenance of transplant 
rejection: (i) they are the first cells to come into 
contact with host leucocytes; (ii) they either express 
or may be induced to express class II MHC (Ia) an- 
tigens [l] and act as antigen presenting cells [2]; 
(iii) they possess also class I MHC antigens (as all 
nucleated cells do) and therefore are obvious 
targets for host cytotoxic T cells, and (iv) they 
regulate traffic of inflammatory leucocytes from 
blood stream into graft parenchyma [3]. Factors 
responisble for upregulation of endothelial antigen 
expression and permeability for leucocytes are in- 
flammatory cytokines, secreted by cells at the site 
of inflammation. Since ECs are not replaced by 
host cells [4], they are potential inducers of rejec- 
tion, ad infinitum. 
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In this communication we demonstrate, by using 
selective inhibitors of eicosanoid synthesis, that 
two effects of y-interferon (gIFN) on rat ECs, the 
enhancement of Ia antigen expression and 
leucocyte adhence, are regulated independently of 
each other and are most likely influenced by in- 
termediary molecules, eicosanoids. 
2. MATERIALS AND METHODS 
2.1. Rats 
The nuclei of colonies of the inbred rat strains Wistar Furth 
(WF; AgB-2, RTlu) and DA (AgB-4, RTla) were obtained 
from Professors 0. Sjdgren (University of Lund, Lund, 
Sweden) and J. Gowans (Dunn School of Pathology, Oxford, 
England), respectively. 
2.2. Endothelial cell cultures 
Endothelial cells were isolated from the hearts of 7-10 days 
old DA rats using a modification of the method of Kasten et al. 
[5,6]. Purity of the EC population was evaluated by indirect im- 
munoperoxidase staining with antibodies against factor VIII 
related antigen (FVIIIr : ag) and leucocyte contamination ex- 
amined with antibody to leucocyte common antigen (LCA). 
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Cultures exceeding 99% of FVIIIr:ag positive cells and no 
detectable LCA expressing cells were used. 
2.3. Antibodies 
Mouse monoclonal antibodies against rat class II MHC an- 
tigen (clone 0X4) and against rat LCA (clone 0X1) were from 
Sera-Lab (Crawley Down, Sussex, England). Rat monoclonal 
antibody against mouse LFA-1 molecule (clone H35.89.9 [7]), 
cross-reacting with rat LFA-1, was a gift from Dr M. Pierres 
(CNRS, Marseille, France). Polyclonal antibodies: rabbit anti- 
mouse IgG conjugated with peroxidase and rabbit anti-human 
FVIIr : ag (cross-reacts with rat FVIIIr : ag) were obtained from 
DAK0 (Copenhagen, Denmark). Goat polyclonal antibody to 
rabbit IgG conjugated with peroxidase was from Tago Inc. 
(Burlingame, CA, USA). 
2.4. Compounds for EC treatment 
Recombinant rat y-interferon was a gift from Dr P.H. van de 
Meide and Dr H. Schellekens (Primate Centre, TNO, Rijswijk, 
The Netherlands). L651.392, an inhibitor of 5-lipoxygenase 181, 
was a gift from Dr A.W. Ford-Hutchison (Merck-Frost, 
Canada). Prostaglandin Er (PGE2) and arachidonic acid (AA) 
were from Upjohn (Calamazoo, MI, USA). Solu-Medrol 
(methylprednisolone) was purchased from Upjohn (Puurs, 
Belgium). 
2.5. Indirect immunoperoxidase taining 
After 3-5 days of culture in bottles, ECs were plated in 
chamber/slides (4 chambers per slide; Miles Scientific, Naper- 
ville, IL, USA) and treated with different compounds for 3 
days. After treatment cells were fixed in situ with 5% parafor- 
maldehyde and labelled with mouse monoclonal or rabbit 
polyclonal antibody, followed by one or two peroxidase con- 
jugated polyclonal antibodies (rabbit anti-mouse IgG and goat 
anti-rabbit IgG). 
2.6. Leucocyte binding to EC 
Binding assay was performed following the modified method 
of Butcher et al. [9]. Compared to the original method, rotation 
of specimens during incubation of ECs with freshly isolated 
spleen cells of WF rat was omitted, because in our experiments 
it did not have an effect on leucocyte binding to ECs. 
3. RESULTS 
Steroids (methylprednisolone; MP) are potent 
inhibitors of eicosanoid synthesis. In the first ex- 
periment we investigated the effect of gIFN on en- 
dothelial cell antigenicity and leucocyte adhesion 
to ECs in the presence or absence of therapeutic 
quantities (1 pug/ml) of MP. For control we used 
PGE2, known from previous studies to inhibit an- 
tigen expression on macrophages [IO]. 
yIFN induced, as expected, potent class II 
MHC expression on ECs and, concomitantly, ECs 
become adherent o allogenic leucocytes (table 1). 
The effect was dose dependent (not shown). At a 
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Table 1 
Effect of inhibition of endothelial eicosanoid synthesis on 
expression of Ia-antigen and leucocyte-endotheiial interaction 
in vitro 
EC treatmenta % of Ia positive % of leucocytes 
ECs binding ECs 
(mean + SD) (mean f SD) 
Nil 8.0 + 1.0 2.3 + 0.6 
gIFNb ’ 50.7 f 2.1*** 20.0 + 1.0*** 
MP 12.7 k 3.1 1.0 f 0.0 
IM 11.3 + 1.1 1.3 f 0.6 
L651.392 7.0 f 1.0 1.0 +_ 0.6 
PGE2 7.0 + 1.0 1.0 * 0.0 
AA 7.0 * 0.0 2.3 + 1.5 
gIFN + MPC 75.7 + 1.5*** 2.7 + 1.5*** 
gIFN + IMC 69.7 + l.S*** 17.3 + 2.1 ns 
gIFN + L65 1.392’ 52.3 + 4.0 ns 10.7 * 2.1** 
gIFN + PGE2’ 36.3 + 1.5*** 20.3 + 2.5 ns 
gIFN + AA’ 49.3 + 2.1 ns 20.1 f 2.5 ns 
gIFN + MP + AA’ 39.3 f 3.1** 17.7 + 2.1 ns 
gIFN + IM + AA’ 66.0 & 2.6** 19.0 f 2.6 ns 
gIFN + L651.392 + AA’ 52.3 * 3.5 ns 10.3 + 3.2; 
a Concentrations: gIFN, 100 U/ml; MP, IM, L651.392, 
1 pg/ml; PGEr, AA, lo-’ M 
b Significancies versus control (line 1) 
’ Significancies versus gIFN treatment alone (line 2) 
Significancies in Student’s t-test: *** p < 0.001, ** p < 0.01, 
* p < 0.1; ns, p > 0.1 (not significant) 
concentration of 1 pg/ml, MP entirely inhibited 
gIFN-induced leucocyte adhesion to ECs, but 
unexpectedly, significantly enhanced endothelial 
expression of Ia antigen. On the other hand, at 
10d7 M, PGE2 reduced gIFN-induced class II 
MHC expression but had no effect on leucocyte- 
endothelial adhesion (table 1). Thus, this experi- 
ment demonstrated that prostaglandins and 
eicosanoid inhibitors can modify gIFN effects on 
endothelium. Secondly, the experiment suggested 
that endothelial Ia expression and adhesiveness for 
leucocytes, when triggered by gIFN, are regulated 
by different molecular pathways and not in- 
terdependent . 
In the second experiment we employed gIFN 
stimulation and selective inhibition for the cyclo- 
oxygenase (CO) or 5lipoxygenase (LO) pathways 
of eicosanoid synthesis, or both, and free 
arachidonic acid (AA). 
MP, indomethacin (IM, inhibitor of CO), 
L65 1.392 (inhibitor of LO), and AA did not alter 
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Table 2 4. DISCUSSION 
Effect of pretreatment of cells with monoclonal antibody on 
leucocyte adherence to endothelium 
EC Antibody Treatment with “Jo of ECs 
stimulation antibodya interacting 
with leuco- 
Endo- Leuco- cytes 
thelium cytes 
Nil 0x4 - _ l-2 
Nil 0x4 + - l-2 
Nil 0x4 - + l-2 
Nil 0x4 + + l-2 
gIFN 0x4 - - 37-69 
glFN 0x4 + - 40-61 
gIFN 0x4 - + 35-38 
gIFN 0x4 + + 35-58 
gIFN H35-89.9 - + l-2 
a Treatment with antibody was performed for 30 min at room 
temperature. Antibody concentration was 0.2 mg/ml 
the background endothelial cell Ia expression 
and/or endothelial cell adherence with leucocytes 
(table 1). When added together with gIFN, MP 
and IM enhanced gIFN-induced Ia expression, but 
L651.392 had no effect. On the other hand, MP 
and L65 1.392 reduced gIFN-induced leucocyte 
adherence to ECs, but IM had no effect. Finally, 
when the same inhibitors were added together with 
gIFN and AA, extraneous AA was able to over- 
come the MP effect, but not the effects of IM and 
L65 1.392. Thus these experiments confirmed that 
eicosanoids are involved in gIFN-induced effects 
on endothelial cells, acting possibly as in- 
termediary (regulatory) molecules, and that whilst 
the leucocyte adhesion to endothelium is regulated 
by the LO pathway, the CO pathway seems to be 
involved in endothelial antigenicity. 
Our results suggest hat the effects of gIFN on 
endothelial cell Ia expression and on the binding of 
allogeneic leucocytes to endothelium are regulated 
by intermediary molecules, eicosanoids. Products 
of the cycle-oxygenase pathway appear to be in- 
volved in the regulation of endothelial class II 
MHC antigen expression, whereas products of the 
lipoxygenase pathway seem to regulate the 
adherence of leucocytes to endothelium. Steroids 
completely block production of eicosanoids by in- 
hibiting the action of phospholipase A2 responsible 
for releasing free arachidonic acid from its cell 
membrane phospholipid-bound form [II]. 
Therefore, enhancing the effect of MP on Ia ex- 
pression appears to be related to the abolition of 
prostaglandin production by the endothelium, 
which seems to function as a ‘natural’ 
downregulatory system for the Ia expression on 
ECs. This conclusion is supported by the finding 
that PGE2 when added to EC cultures together 
with gIFN, had an inhibitory effect on class II 
MHC expression. IM, which blocks the production 
of prostaglandins by interfering with cyclo- 
oxygenase activity, had an MP-like effect on Ia ex- 
pression. 
Finally, we wished to formally demonstrate that 
the gIFN effects on endothelial Ia expression and 
leucocyte adhesion to endothelium are indepen- 
dent of each other, by attempting to inhibit the 
leucocyte adhesion to endothelium with anti-class 
II MHC antigen antibody. The results are shown in 
table 2. Treatment of the endothelial cells, or the 
leucocytes or both with antibody OX4 did not alter 
the leucocyte adhesion to the endothelium. In- 
stead, treatment of leucocytes with antibody to 
LFA-1 molecule (control), entirely inhibited the 
adherence. 
In addition to the effect on Ia expression, 
steroids also appear to affect leucocyte-endothelial 
adherence. The most probable reason is the block- 
ing of lipoxygenase pathways, by cutting off free 
arachidonic acid supply. This suggestion is con- 
firmed by the suppressive effect of the 
5-lipoxygenase inhibitor, L561.392, on leucocyte 
binding to ECs, and restoration by AA when add- 
ed together with MP. Incomplete inhibition of 
binding by L651.392, compared to MP, is caused 
most likely by the presence of other lipoxygenase 
pathways in ECs (e.g. 15-lipoxygenase pathway), 
which can produce other binding-stimulating 
mediators (e.g. 15-HETE) [12]. Leukotriene B4, a 
product of the 5-lipoxygenase pathway, has 
already been shown to enhance the adherence of 
leucocytes to endothelial cells [13]. 
Finally, in contradiction to the results of 
Masuyama et al. [14], we did not find Ia antigen to 
be involved in leucocyte binding to the en- 
dothelium. Regulation of Ia expression, by dif- 
ferent mediators or blocking of Ia antigen with 
monoclonal antibody, did not have any effect on 
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leucocyte-endothelial interaction. For comparison, 
treatment of leucocytes with monoclonal antibody 
against LFA-1 molecule [ 151 showed complete in- 
hibition of leucocyte-endothelial binding. 
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